

G6PD deficiency

Ghasem Miri-Aliabad ,MD
Professor of Pediatric Hematology–
Oncology

The Red Cell

- ❖ Average life span
 - Adult: 120 days
 - Neonate: 60–90 days
 - Premature infants: 40–60 days
- ▶ Hemolytic anemias = reduced red cell life span

Hemolytic anemias

- ❖ Corpuscular (Intrinsic) or Extracorporeal(Extrinsic)
- ❖ Acquired or hereditary

Classification of Hemolytic anemias

❖ Corpuscular

- RBC membrane defects
 - HS, HE
- Enzyme defects
 - PK, G6PD
- Hemoglobin defects
 - Heme:
 - Globin: 1) quantitative: thalassemia
2) qualitative: Sickle cell


❖ Extracorpuscular

- Immune (Isoimmune, Autoimmune, Alloimmune)
- Nonimmune

❖ Extracorpuscular

- Immune (Isoimmune, Autoimmune, Alloimmune)
 - Nonimmune
-
- ▶ Autoimmune: Idiopathic, Secondary
 - ▶ Nonimmune: Idiopathic, Secondary

Normal RBC






خانه شهر سوخته شهرستان رابل دوره ۳۲۰۰ قبل از میلاد

Enzyme defects


G6PD Deficiency

- MOST COMMON HUMAN ENZYME DEFECT
 - Affecting 400–500 million people worldwide
 - X-lined recessive, different variants of the disease
 - Enzyme deficient red blood cells
 - Higher prevalence in Mediterranean's, Blacks
 - DECREASE IN GLUTATHIONE LEVELS
- 

G6PD DEFICIENCY



- ▶ Enzyme deficient RBC are unable to defend against **oxidant stress** (infection, drugs) and form **Heinz bodies** (denatured hemoglobin) which are phagocytosed by splenic macrophages, creating “bites” on cells
- ▶ Heinz bodies appear as granules in RBC's

HEINZ bodies



Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

- ▶ A^{-} and Mediterranean are most significant types



G6PD DEFICIENCY

Clinical manifestations

- ▶ Neonatal Jaundice
- ▶ Acute hemolytic anemia
- ▶ Chronic nonspherositic hemolytic anemia

G6PD DEFICIENCY

Acute hemolytic crisis

- ▶ Can be triggered by
 - ❖ Foods (fava beans)
 - ❖ Oxidant substances drugs
 - ❖ Infections
 - ❖ DKA

AGENTS PRECIPITATING HEMOLYSIS IN G6PD DEFICIENCY

▶ Antibacterials

- ▶ Sulfonamides
- ▶ Dapsone
- ▶ TMP-SMS
- ▶ Nalidixic acid
- ▶ Chloramphenicol
- ▶ Nitrofurantoin

▶ Antimalarials

- ▶ Primaquine
- ▶ Pamaquine
- ▶ Chloroquine
- ▶ Quinacrine

▶ Others

- ▶ Acetanilide
- ▶ Vitamin K analogs
- ▶ Methylene blue
- ▶ Probenecid
- ▶ ASA
- ▶ Phenazopyridine

▶ CHEMICALS

- ▶ Phenylhydrazine
- ▶ Benzene
- ▶ Naphthalene

▶ ILLNESS

- ▶ DKA
- ▶ Hepatitis
- ▶ Sepsis

TABLE 17-3 Drugs That Can Trigger Hemolysis in G6PD-Deficient Children*

Category of Drug	Definite Risk	Possible Risk
Antimalarials	Primaquine Dapsone-containing combinations [†]	Chloroquine Quinine
Analgesics	Acetanilid	Aspirin
Sulfonamides/ sulfones	Sulfamethoxazole/ co-trimoxazole Dapsone [†]	Sulfasalazine Sulfadiazine
Quinolones	Nalidixic acid Ciprofloxacin Norfloxacin Moxifloxacin Ofloxacin	
Other antimicrobials	Nitrofurantoin Methylene blue	Chloramphenicol
Other	Niridazole	Vitamin K Rasburicase Ascorbic acid Glibenclamide

G 6 P D deficiency

Clinically

- ❖ Most individuals with G6PD deficiency are asymptomatic
- ❖ Usually no evidence of hemolysis is apparent until 24-48 hours after the patient has ingested a substance which has oxidant properties

► **Acute intravascular hemolysis can occur:**

- Hemoglobinuria
- Dark urine
- Hemoglobinemia
- Anemia
- Jaundice



G 6 P D deficiency

Diagnosis

❖ History

❖ **Lab Tests:** CBC, PBS, Retic, Na, K, BUN, Cr , AST, ALT, Bili, LDH, BG, Rh, Direct Coombs, G6PD, U/A

❖ Low G6PD activity in RBC

❖ G6PD assay best done when not in acute crisis as retic count is high

G 6 P D deficiency

Treatment: SUPPORTIVE , PREVENTATIVE

1. Hydration

2. Indications for Red blood cell transfusion

3. Education of families and patients

4. Folic Acid

Prevention

Avoiding ingestion of fava beans or oxidant substances



